建立了一种简便、灵敏的氯甲酸芴甲酯(FMOC-Cl)柱前衍生反相高效液相色谱-荧光检测血浆中奈替米星的新方法,同时研究了其药代动力学.对色谱条件进行了优化,采用ZORBAX Eclipse XDB-C_8柱(150 mm×4.6 mm,5 μm),流动相为乙腈-水(体积比为85∶15),流速为1.0 mL/min,荧光检测激发波长为265 nm,发射波长为315 nm,得到奈替米星的平均加标回收率为96.62% ～100.84%(n=3),对奈替米星检测的线性范围为0.045～8.88 mg/L,相关系数为 0.999 3,方法的日内与日间精密度分别低于3%与3.5%,最低检出限(S/N=3)与定量限(以3倍检出限计)分别为0.01和0.03 mg/L.方法简便、快速、灵敏,样品用量少(30 μL奈替米星血浆溶液已能满足该药含量的测定以及药物代谢的研究),为大鼠体内奈替米星的药代动力学研究提供了可靠的分析手段.
A new, simple and sensitive method based on pre-column derivatization by reversed-phase high performance liquid chromatography (HPLC) is described for the separation and quantification of netilmicin in plasma, using 9-fluorenylmethyl chloroformate (FMOC-Cl) as the derivatization reagent. Its pharacokinetics is also presented. The derivatization modes and chromatographic conditions were optimized. The separation was performed on an Agilent ZOR-BAX Eclipse XDB-C_8 column (150 mm ×4. 6 mm, 5 μm) with a mixture of water-acetonitile (15:85, v/v) as mobile phase and the flow rate was 1.0 mL/min. The excitation wavelength was 265 nm and the emission wavelength was 315 nm. The linear range was 0. 045-8. 88 mg/L and the correlation coefficient (r) was 0. 999 3. The limit of detection (LOD) (S/N = 3) was about 0.01 mg/L, and the limit of quantification was 0.03 mg/L (3LOD) for netilmicin. The relative standard deviation was less than 3% for intra-day assay (n =5) and 3. 5% for inter-day assay (n = 5) and the relative recovery was in the range of 96. 62% - 100. 84% (n = 3). The plasma volume of 30 μL was sufficient for the determination of netilmicin. The method provides a reliable bioanalytical methodology to carry out netilmicin pharmacokinetics in rat plasma.
参考文献
| [1] | Wright J J.J Chem Soc Chem Commun,1976,6:206 |
| [2] | Adams E,Puelings D,Rafiee M,et al.J Chromatogr A,1998,812:151 |
| [3] | Shawar R M,MacLeod D L,Garber R L,et al.Antimicrob Agents Chemother,1999,43(12):2 877 |
| [4] | Andrews J M,Wise R.Antimicrob Chem,1984,14:509 |
| [5] | Wang Y S,Luo Z H,Zhang H F,et al.Journal of General Hospital of Air Force,PLA (王岳松,罗志红,张华峰,等.空军总医院学报),2000,16(1):43 |
| [6] | Yu H,Deng Y,Li X M.Medical Journal of National Defending Forces in North China (于弘,邓源,李秀敏.华北国防医药),2006,18(4):289 |
| [7] | Yang W C,Yu A M,Chen H Y.J Chromatogr A,2001,905:309 |
| [8] | Calcara M,Enea V,Pricoco A,et al.J Pharm Biomed Anal,2005,38:344 |
| [9] | Flurer C L,Wolnik K A.J Chromatogr A,1994,663:259 |
| [10] | Yi A,Liu Z F,Liu S P,et al.Luminescence,2009,24:23 |
| [11] | Bhogte C P,Patravale V B,Devarajan P V.J Chromatogr B,1997,694:443 |
| [12] | Mayhew J W,Gorbach S L.J Chromatogr,1978,151:133 |
| [13] | Vogel R,DeFillipo K,Reif V.J Pharm Biomed Anal,2001,24:405 |
| [14] | Kaine L A,Wolnik K A.J Chromatogr A,1994,674:255 |
| [15] | Zawilla N H,Diana J,Hoogmartens J,et al.J Chromatogr B,2006,833:191 |
| [16] | Yuan C,Wang J X,Jia N,et al.Chinese Pharmacological Bulletin (袁成,王景祥,贾暖,等.中国药理学通报),1998,14(2):180 |
| [17] | Yuan C,Zhu L Q,Wang J X,et al.Chinese Pharmaceutical Journal (袁成,朱丽青,王景祥,等.中国药学杂志),1999,34(11):755 |
| [18] | Liu Z,Sha Y F,Huang T M,et al.J Chromatogr B,2005,828:2 |
| [19] | Kim B H,Kim Y K,Ok J H.J Chromatogr B,2001,752:173 |
| [20] | Wang L F,Peng J D.Chromatographia,2009,69(5/6):519 |
| [21] | Santos M,Garcia E,López F G,et al.J Pharm Biomed Anal,1995,13:1 059 |
| [22] | Peng G W,Jackson G G,Chiou W L.Antimicrob Agents Chemother,1977,12(6):707 |
| [23] | Isoherranen N,Soback S.Clin Chem,2000,46(6):837 |
| [24] | Zhou M J,Wei G L,Liu Y P,et al.J Chromatogr B,2003,798:43 |
| [25] | Suhren G,Knappstein K.Analyst,1998,123:2 797 |
| [26] | McLaughlin L G,Henion J D,Kijak P J.Biol Mass Spectrom,1994,23:417 |
| [27] | Hu P F,Chess E K,Brynjelsen S,et al.J Am Soc Mass Spectrom,2000,11:200 |
| [28] | L(o)ffler D,Ternes T A.J Chromatogr A,2003,1 000:583 |
- 下载量()
- 访问量()
- 您的评分：
-
10%
-
20%
-
30%
-
40%
-
50%